Dr. Efstathios Kastritis, National and Kapodistrian University of Athens, presents a summary real world evidence for the efficacy and clinical use of selinexor combinations, as well as the post-progression therapies and their outcome

Background:

Selinexor is the first in class, orally available, exportin inhibitor, approved for heavily pretreated, triple class refractory myeloma patients (pts) in combination with dexamethasone (Sd) and in pts with relapsed/refractory myeloma (RRMM) with 1-3 prior lines of therapy in combination with bortezomib and dexamethasone (SVd). In clinical practice, the use of selinexor is associated with gastrointestinal toxicity, appetite loss and fatigue which require aggressive management, and may limit its use, especially outside the context of a clinical trial. In this report we sought to provide “real world” evidence for the efficacy and clinical use of selinexor combinations, as well as the post-progression therapies and their outcome.

Conclusions:

In conclusion, outside the context of clinical trials, the efficacy of selinexor combinations in heavily pretreated RRMM pts is moderate, with responding pts having a higher probability for longer remissions. OS in this heavily pretreated population, however, exceeds 1 year and sets the benchmark for the evaluation of new therapies. Dose adjustments are required in most pts indicating that optimal dose of selinexor may be lower than the recommended. The prognostic impact of low serum albumin in these pts needs further evaluation as it may be a marker of poor nutrition, advanced disease and poor tolerance to selinexor.

Authors:

Efstathios Kastritis, MD, Panagiotis Malandrakis, MD, Vasiliki Spiliopoulou, MD, Ioannis Ntanasis-Stathopoulos, MD, Eirini Solia, Foteini Theodorakakou, MD, Rodanthi Syrigou, MD, Nikoletta-Aikaterini Kokkali, Magdalini Migkou, MD, Evangelos Eleutherakis Papaiakovou, MD, Despina Fotiou, MD, Maria Roussou, MD, Nikolaos Kanellias, MD, Maria Gavriatopoulou, MD, Evangelos Terpos, MD, PhD and Meletios A. Dimopoulos, MD

ASH Abstract #3181: https://ash.confex.com/ash/2022/webprogram/Paper165924.html (https://ash.confex.com/ash/2022/webprogram/Paper165924.html)